KR20220061967A - DcR3 개변체 - Google Patents

DcR3 개변체 Download PDF

Info

Publication number
KR20220061967A
KR20220061967A KR1020227007739A KR20227007739A KR20220061967A KR 20220061967 A KR20220061967 A KR 20220061967A KR 1020227007739 A KR1020227007739 A KR 1020227007739A KR 20227007739 A KR20227007739 A KR 20227007739A KR 20220061967 A KR20220061967 A KR 20220061967A
Authority
KR
South Korea
Prior art keywords
dcr3
amino acid
acid sequence
variant
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227007739A
Other languages
English (en)
Korean (ko)
Inventor
아키코 가나이
히토미 호소미
사키코 요네자와
Original Assignee
쿄와 기린 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쿄와 기린 가부시키가이샤 filed Critical 쿄와 기린 가부시키가이샤
Publication of KR20220061967A publication Critical patent/KR20220061967A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227007739A 2019-09-13 2020-09-11 DcR3 개변체 Pending KR20220061967A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019167728 2019-09-13
JPJP-P-2019-167728 2019-09-13
PCT/JP2020/034444 WO2021049606A1 (ja) 2019-09-13 2020-09-11 ＤｃＲ３改変体

Publications (1)

Publication Number Publication Date
KR20220061967A true KR20220061967A (ko) 2022-05-13

Family

ID=74865719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227007739A Pending KR20220061967A (ko) 2019-09-13 2020-09-11 DcR3 개변체

Country Status (10)

Country Link
US (1) US20220340642A1 (https=)
EP (1) EP4056232B1 (https=)
JP (2) JP7679300B2 (https=)
KR (1) KR20220061967A (https=)
CN (3) CN121930331A (https=)
AU (1) AU2020346580A1 (https=)
BR (1) BR112022004590A2 (https=)
CA (1) CA3154191A1 (https=)
TW (1) TW202124425A (https=)
WO (1) WO2021049606A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
US20230159649A1 (en) * 2020-04-02 2023-05-25 La Jolla Institute For Immunology Methods and combinations for dual targeting of tnf family members
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
EP4370545A1 (en) * 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
TW202545974A (zh) * 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT311902B (de) 1970-04-29 1973-10-15 Herrmann W Ionenaustauschfilter,insbesondere kleinfilter
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
BRPI0519008A2 (pt) * 2004-12-13 2008-12-23 Evogenix Ltd proteÍnas variantes de osteoprotegerina
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
EP2653540B9 (en) 2010-12-15 2018-05-16 Inter-University Research Institute Corporation Research Organization of Information and Systems Protein production method
US20140193410A1 (en) * 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
ES2894963T3 (es) * 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
EP3730188B1 (en) * 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 285: p.G754-G760
Biochemical Pharmacology, 2011, 81: p.838-847
Drug Metabolism and Disposition, 2003, 31: p.502-507
Immunology, 2009, 128: p.451-458
J. Immunol., 2006, 176: p.173-180
Journal of Biomedical Science, 2017, 24: 39
Nature Reviews Cancer, 2002. 2: p.420-430
Nature Reviews Drug Discovery, 2013, 12: p.147-168
P.N.A.S., 2006, 103: p.8441-8446
Structure, 2011, 19: p.162-171
Structure, 2014, 22: p.1252-1262
Structure, 2016, 24: p.2016-2023

Also Published As

Publication number Publication date
TW202124425A (zh) 2021-07-01
BR112022004590A2 (pt) 2022-06-14
CN114450301A (zh) 2022-05-06
CN114450301B (zh) 2025-12-05
JP7679300B2 (ja) 2025-05-19
US20220340642A1 (en) 2022-10-27
WO2021049606A1 (ja) 2021-03-18
AU2020346580A1 (en) 2022-03-31
EP4056232A4 (en) 2023-09-13
JPWO2021049606A1 (https=) 2021-03-18
EP4056232B1 (en) 2026-05-06
EP4056232A1 (en) 2022-09-14
CN121930331A (zh) 2026-04-28
JP2025121978A (ja) 2025-08-20
CA3154191A1 (en) 2021-03-18
CN121949515A (zh) 2026-05-01

Similar Documents

Publication Publication Date Title
JP7679300B2 (ja) ＤｃＲ３改変体
KR102884523B1 (ko) IL-12 이종이량체 Fc-융합 단백질
CN111138542B (zh) 双特异性抗体及其用途
JP7662516B2 (ja) Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
AU2012317418B2 (en) Antigen-binding molecule for promoting elimination of antigens
KR102854939B1 (ko) ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
TWI760396B (zh) 抗肌抑素抗體及使用方法
RU2722829C9 (ru) Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
KR102475951B1 (ko) ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
KR20210003814A (ko) IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
KR20190014525A (ko) 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
JP2023521582A (ja) 改変Ｃ末端ｃｒｏｓｓｆａｂ断片を含む二重特異性抗体
KR20210003813A (ko) IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
KR20140015501A (ko) 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
JP2021525065A (ja) Ｉｌ−１ｒ１結合ドメインおよび運搬部分を含むポリペプチド
JP6840907B2 (ja) ＦＧＦＲ３結合分子ｌｋｏｋｏｋ
JPWO2020067541A1 (ja) 抗体組成物
WO2021201236A1 (ja) 抗体組成物
CN120641443A (zh) 特异性结合tnf-样配体1a（tl1a）的单克隆抗体或其抗原结合片段及其用途
CN121532432A (zh) 免疫治疗蛋白
JP7833531B2 (ja) Ｃｄ４０を特異的に認識する抗体およびその使用
HK40067776A (en) Dcr3 variant
TWI917846B (zh) 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
RU2772771C1 (ru) Антигенсвязывающая молекула для ускорения элиминации антигенов
RU2799423C1 (ru) Способ изменения удержания в плазме и иммуногенности антигенсвязывающей молекулы

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000